[
    {
        "pregunta": "1. What is the recommended frequency for screening people with SLE for proteinuria in the absence of known kidney disease?",
        "respuesta": "The provided information states that in people with systemic lupus erythematosus (SLE) without known kidney disease, it is strongly recommended to screen for proteinuria at least every 6-12 months, or when experiencing extra-renal flares.",
        "contexto": [
            "and Treatment Recommendations and Good Practice Statements SCREENING: In people with SLE without known kidney disease, we strongly recommend screening for proteinuria at least every 6-12 months, OR when experiencing extra-renal flares. KIDNEY BIOPSY: GPS: Prompt kidney biopsy should be performed in people with SLE when LN is suspected (unless contraindicated/not feasible). In people with SLE who have proteinuria >0.5 g/g and/or impaired kidney function not otherwise explained, we conditionally",
            "and age-related decline in GFR in this population. MONITORING: In people with LN who have not achieved complete renal response, we strongly recommend quantifying proteinuria at least every 3 months. In people with LN with sustained complete renal response, we strongly recommend quantifying proteinuria every 3-6 months. GPS: In people with LN, serum complement levels and anti-dsDNA antibody concentrations should be checked at every clinic visit but not more frequently than monthly. RENAL",
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "aspirin 81 mg daily as prophylaxis in all patients at high risk for preeclampsia Because active disease affects maternal and pregnancy outcome, we strongly suggest, as good practice, monitoring SLE disease activity with clinical history, examination, and laboratory tests at least once per trimester. Abnormalities in the complete blood cell count, differential cell count, urinalysis results and urinary protein:creatinine ratio, or anti-DNA, C3, or C4 levels may indicate possible SLE flare and/or",
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular"
        ]
    },
    {
        "pregunta": "2. When is a kidney biopsy strongly recommended in people with SLE suspected of having lupus nephritis?",
        "respuesta": "A kidney biopsy is strongly recommended for people with systemic lupus erythematosus (SLE) when lupus nephritis is suspected, unless it is contraindicated or not feasible.",
        "contexto": [
            "and Treatment Recommendations and Good Practice Statements SCREENING: In people with SLE without known kidney disease, we strongly recommend screening for proteinuria at least every 6-12 months, OR when experiencing extra-renal flares. KIDNEY BIOPSY: GPS: Prompt kidney biopsy should be performed in people with SLE when LN is suspected (unless contraindicated/not feasible). In people with SLE who have proteinuria >0.5 g/g and/or impaired kidney function not otherwise explained, we conditionally",
            "and/or impaired kidney function not otherwise explained, we conditionally recommend performing a kidney biopsy. For people with treated LN in remission who present with suspected LN flare (increased proteinuria, hematuria, and/or worsening kidney function), OR for people with ≥6 months of appropriate treatment and ongoing/worsening proteinuria, hematuria, and/or decreased kidney function, we conditionally recommend repeat kidney biopsy. TREATMENT OF ACTIVE LN (CLASS III/IV OR CLASS V): GPS:",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "or early in pregnancy in women with SLE or SLE-like disorders, Sjögren's syndrome, systemic sclerosis, and rheumatoid arthritis. Given the relative persistence and unchanged titers of these antibodies, we strongly recommend against repeating the test during pregnancy. Patients with scleroderma renal crisis. Most diseasespecific recommendations for RMD pregnancy management focus on presence of underlying SLE or positive aPL. One aspect of disease in systemic sclerosis, however, is of particular",
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally"
        ]
    },
    {
        "pregunta": "3. What is the preferred therapy regimen for lupus nephritis according to the ACR guideline?",
        "respuesta": "The provided information does not include specific details about the preferred therapy regimen for lupus nephritis according to the American College of Rheumatology (ACR) guideline. Therefore, I am unable to provide a reliable response based on the available information.",
        "contexto": [
            "2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis      E755A258B54DE5A9A9F006899726219C This summary was approved by the ACR Board of Directors on November 15, 2024. These recommendations are included in a full manuscript, which will be submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Lupus Nephritis Screening and Treatment Recommendations and Good Practice Statements SCREENING: In",
            "Methodology overview. This guideline followed the American College of Rheumatology (ACR) guideline development process ( http://www.rheumatology.org/Practice-Quality/ Clinical-Support/Clinical-Practice-Guidelines http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract http://onlinelibrary.wiley.com/doi/10.1002/art.40726/abstract In addressing pharmacologic therapies, we focused on immunomodulatory agents for long-term management rather than addressing acute symptom management (i.e.,",
            "inflammatory condition, and improved outcomes occur with early diagnosis, evaluation, and management. The American College of Rheumatology (ACR) has previously published pharmacologic guidelines to aid clinicians and individuals with RA 1 METHODS This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures ( https://rheumatology.org/clinical-practiceguidelines https:// onlinelibrary.wiley.com/doi/10.1002/acr.25117",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "medications in patients with severe SLE would merit review by the treating rheumatologist in consideration of surgery. The Voting Panel agreed with their inclusion via email voting. This guideline is informed by cohort studies including pharmacoepidemiologic studies using large administrative databases. To our knowledge, there have been no randomized controlled trials since the publication of the prior ACR/AAHKS guideline in 2017, so much of the data supporting these recommendations remains"
        ]
    },
    {
        "pregunta": "4. How should medication dosages be adjusted in individuals with decreased GFR at the initiation of lupus nephritis therapy?",
        "respuesta": "The provided information does not include specific guidelines regarding adjusting medication dosages based on decreased glomerular filtration rate (GFR) when initiating therapy for lupus nephritis. Therefore, I am unable to provide a reliable response based on the available information.",
        "contexto": [
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "low-dose allopurinol (≤100 mg/day and lower in patients with CKD [stage ≥3] ) and febuxostat (≤40 mg/day) with subsequent dose titration over starting at a higher dose is strongly recommended. Starting treatment with low-dose probenecid (500 mg once to twice daily) with subsequent dose titration over starting at a higher dose is conditionally recommended. A lower starting dose of any ULT reduces the risk of flare associated with initiation Certainty of evidence For patients starting any ULT, we",
            "to target over starting at a higher dose (e.g., <100 mg/day [and lower in patients with CKD] for allopurinol or <40 mg/day for febuxostat). Moderate For probenecid, we conditionally recommend starting at a low dose (500 mg once or twice daily) with dose titration over starting at a higher dose. We strongly recommend initiating concomitant antiinflammatory prophylaxis therapy (e.g., colchicine, NSAIDs, prednisone/prednisolone) over no antiinflammatory prophylaxis. The choice of specific"
        ]
    },
    {
        "pregunta": "5. When should adjunctive treatment with systemic anticoagulation be considered for individuals with lupus nephritis?",
        "respuesta": "The provided information does not include specific guidelines about when adjunctive treatment with systemic anticoagulation should be considered for individuals with lupus nephritis. Therefore, I am unable to provide a reliable response based on the available information.",
        "contexto": [
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "thrombotic event (arterial or venous), regardless of whether they have had obstetric complications; IVIG = intravenous immunoglobulin; PICO = population, intervention, comparator, outcomes. Continue HCQ (if on) LEGEND Against prednisone We recommend that all women with SLE take hydroxychloroquine (HCQ) during pregnancy if possible. If a patient is already taking HCQ, we strongly recommend continuing it during pregnancy; if she is not taking HCQ, we conditionally recommend starting it if there",
            "<h1>Recommendation pertains to infection risk and does not account for risk of cardiac events or venous thromboembolism.</h1>\n\n<h1>RESULTS/RECOMMENDATIONS</h1>\n\n<h1>Table 3. Recommendations for perioperative management of anti-rheumatic drug therapy in patients with inflammatory arthritis and those with systemic lupus erythematosus (SLE) undergoing elective total hip arthroplasty (THA) or total knee arthroplasty (TKA)*</h1>",
            "excluded, including noninflammatory etiologies such as hypertensive, diabetic, and medication-induced nephropathy. ADJUNCTIVE/NON-IMMUNOLOGIC TREATMENT: GPS: Adjunctive and non-immunologic therapies and practices should be initiated in addition to appropriate immunosuppressive therapy to improve overall kidney health. Management of cardiovascular health, bone health, infection risk, and reproductive concerns should be addressed.* GPS: In children with childhood-onset SLE (cSLE) and LN,",
            "additional treatments are needed for patients who do not respond to standard therapy. Intravenous immunoglobuin, low-dose prednisone, increased dose of heparin/LMWH, and HCQ have all been suggested as additional or alternative treatments. We conditionally recommend against treatment with intravenous immunoglobulin or an increased LMWH dose, as these have not been demonstrably helpful in cases of pregnancy loss despite standard therapy with low-dose aspirin and prophylactic heparin or LMWH."
        ]
    },
    {
        "pregunta": "6. What is the recommended duration of therapy for individuals who have achieved sustained complete renal response after treatment with immunosuppressive therapy?",
        "respuesta": "For individuals with lupus nephritis who have achieved sustained complete renal response after treatment with any (triple or dual) immunosuppressive therapy, it is conditionally recommended to have a total duration of therapy of at least 3-5 years.",
        "contexto": [
            "recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With proteinuria ≥1 g/g we conditionally recommend treatment with a TRIPLE immunosuppressive regimen consisting of pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend",
            "this guideline, we emphasize the importance of prompt kidney biopsy and LN treatment and propose triple therapy as the most desirable therapy for LN, preferring MPAA regimens over CYC regimens. We propose a lower dose glucocorticoid regimen to minimize toxicity, with a prednisone goal of ≤5 mg/day by 6 months of therapy, and a total therapy duration of 3-5 years for those achieving complete renal response. Discussion between clinicians and patients is critical because multiple factors impact",
            "we conditionally recommend the addition of RAAS-I. …We conditionally recommend pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper to a target dose of ≤5mg/day by 6 months. … Who have achieved/sustained a complete renal response after treatment with any (triple or dual) immunosuppressive therapy, we conditionally recommend a total duration of therapy of at least 3-5 years. IN PEOPLE"
        ]
    },
    {
        "pregunta": "7. In individuals with active or new onset lupus nephritis Class V, what is the recommended treatment for proteinuria levels above 1 g/g?",
        "respuesta": "For individuals with active or new-onset lupus nephritis Class V and proteinuria levels ≥1 g/g, it is conditionally recommended to treat with a triple immunosuppressive regimen consisting of pulse intravenous glucocorticoids (250-1000 mg methylprednisolone daily for 1-3 days), followed by oral glucocorticoids (≤0.5 mg/kg/day, with a maximum dose of 40 mg/day) with taper, along with mycophenolic acid analog (MPAA) and a calcineurin inhibitor (CNI).",
        "contexto": [
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "recommend a total duration of therapy of at least 3-5 years. IN PEOPLE WITH ACTIVE IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF PURE CLASS V: …With proteinuria ≥1 g/g we conditionally recommend treatment with a TRIPLE immunosuppressive regimen consisting of pulse intravenous glucocorticoids 250-1000 mg methylprednisolone daily x 1-3 days, followed by oral glucocorticoid ≤0.5 mg/kg/day (maximum dose 40 mg/day) with taper and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "and Treatment Recommendations and Good Practice Statements SCREENING: In people with SLE without known kidney disease, we strongly recommend screening for proteinuria at least every 6-12 months, OR when experiencing extra-renal flares. KIDNEY BIOPSY: GPS: Prompt kidney biopsy should be performed in people with SLE when LN is suspected (unless contraindicated/not feasible). In people with SLE who have proteinuria >0.5 g/g and/or impaired kidney function not otherwise explained, we conditionally",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,"
        ]
    },
    {
        "pregunta": "8. How should non-responsive or refractory lupus nephritis be managed according to the ACR guideline?",
        "respuesta": "For individuals with non-responsive or refractory lupus nephritis, according to the information provided, the American College of Rheumatology guideline conditionally recommends treatment escalation. This can include the addition of anti-CD20 agents, combination therapy with three non-glucocorticoid immunosuppressives (such as mycophenolic acid analog, belimumab, and calcineurin inhibitor), or referral for investigational therapy. Medication dosage and patient adherence should also be assessed as an initial step in evaluating inadequate response or refractory lupus nephritis, as insufficient treatment is a common cause of non-response.",
        "contexto": [
            "2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis      E755A258B54DE5A9A9F006899726219C This summary was approved by the ACR Board of Directors on November 15, 2024. These recommendations are included in a full manuscript, which will be submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Lupus Nephritis Screening and Treatment Recommendations and Good Practice Statements SCREENING: In",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "Methodology overview. This guideline followed the American College of Rheumatology (ACR) guideline development process ( http://www.rheumatology.org/Practice-Quality/ Clinical-Support/Clinical-Practice-Guidelines http://onlinelibrary. wiley.com/doi/10.1002/art.40726/abstract http://onlinelibrary.wiley.com/doi/10.1002/art.40726/abstract In addressing pharmacologic therapies, we focused on immunomodulatory agents for long-term management rather than addressing acute symptom management (i.e.,",
            "inflammatory condition, and improved outcomes occur with early diagnosis, evaluation, and management. The American College of Rheumatology (ACR) has previously published pharmacologic guidelines to aid clinicians and individuals with RA 1 METHODS This guideline follows the ACR guideline development process and ACR policy guiding management of conflicts of interest and disclosures ( https://rheumatology.org/clinical-practiceguidelines https:// onlinelibrary.wiley.com/doi/10.1002/acr.25117"
        ]
    },
    {
        "pregunta": "9. What is the suggested escalation of treatment for individuals with inadequate renal response to initial DUAL therapy?",
        "respuesta": "For individuals with lupus nephritis who have an inadequate renal response to initial dual therapy (i.e., they have not achieved at least a partial renal response by 6-12 months), the American College of Rheumatology guideline conditionally recommends escalating to triple therapy.",
        "contexto": [
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "and MPAA plus CNI. … With proteinuria <1 g/g, we conditionally recommend treatment with glucocorticoids and/or immunosuppressant therapy (MPAA, AZA, or CNI). IN PEOPLE WITH NONRESPONSIVE OR REFRACTORY LN: GPS: Medication dose and patient adherence should be assessed as an important first step in evaluating inadequate response or refractory LN, as insufficient treatment is an important cause of non-response. In people with any LN class with an inadequate renal response (i.e., have not achieved",
            "2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis      E755A258B54DE5A9A9F006899726219C This summary was approved by the ACR Board of Directors on November 15, 2024. These recommendations are included in a full manuscript, which will be submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Lupus Nephritis Screening and Treatment Recommendations and Good Practice Statements SCREENING: In",
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally"
        ]
    },
    {
        "pregunta": "10. When should referral for investigational therapy be considered in individuals with refractory lupus nephritis?",
        "respuesta": "According to the information provided, for individuals with refractory lupus nephritis (i.e., those who have failed two standard therapy courses), the American College of Rheumatology guideline conditionally recommends consideration of referral for investigational therapy.",
        "contexto": [
            "medications in patients with severe SLE would merit review by the treating rheumatologist in consideration of surgery. The Voting Panel agreed with their inclusion via email voting. This guideline is informed by cohort studies including pharmacoepidemiologic studies using large administrative databases. To our knowledge, there have been no randomized controlled trials since the publication of the prior ACR/AAHKS guideline in 2017, so much of the data supporting these recommendations remains",
            "(i.e., failed two standard therapy courses), we conditionally recommend treatment escalation to a more intensive regimen, including addition of anti-CD20 agents, or combination therapy with three non-glucocorticoid immunosuppressives (i.e., MPAA, belimumab and CNI), or referral for investigational therapy. OTHER LUPUS KIDNEY DISEASE: GPS: Alternative etiologies of kidney dysfunction in people with SLE should be carefully excluded, including noninflammatory etiologies such as hypertensive,",
            "2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis      E755A258B54DE5A9A9F006899726219C This summary was approved by the ACR Board of Directors on November 15, 2024. These recommendations are included in a full manuscript, which will be submitted for publication in Arthritis & Rheumatology and Arthritis Care and Research.  Lupus Nephritis Screening and Treatment Recommendations and Good Practice Statements SCREENING: In",
            "LN and significant risk factors for thrombosis (e.g., low serum albumin in context of severe proteinuria) should be discussed with nephrology. IN PEOPLE WITH ACTIVE/NEW ONSET/FLARE OF CLASS III/IV OR CLASS V: …If not on HCQ, we strongly recommend initiation and continuation of HCQ to manage and prevent lupus clinical manifestations, unless contraindicated. …With any elevation in level of proteinuria, including <0.5g/g, we conditionally recommend the addition of RAAS-I. …We conditionally",
            "any LN class with an inadequate renal response (i.e., have not achieved at least a partial renal response by 6-12 months) we conditionally recommend escalation of treatment: • For initial DUAL therapy, escalate to TRIPLE therapy. • For initial TRIPLE therapy, change to an alternative TRIPLE therapy or consider addition of an anti-CD20 agent as a second immunosuppressive. In people with any LN class with refractory disease (i.e., failed two standard therapy courses), we conditionally recommend"
        ]
    }
]